On October 31, AbbVie and EvolveImmune Therapeutics announced a collaboration. The partnership will combine AbbVie's oncology expertise with EvolveImmune's proprietary EVOLVE T-Cell Engager Platform to develop novel multispecific therapeutic antibodies for cancer targeting multiple antigens.Under the terms of the agreement, EvolveImmune will receive an upfront payment and equity investment totaling $65 million from AbbVie, and is eligible to receive up to $1.4 billion in option fees and milestone payments, as well as tiered royalties on net sales.EvolveImmune was founded in 2018 and is committed to developing next-generation biological therapies to overcome cancer cell resistance to current immunotherapies. Institutions such as Pfizer Ventures, Takeda Ventures, and BMS have participated in the company's previous financing rounds.EvolveImmune's core technology platform is EVOLVE, aiming to achieve potent, selective, and integrated T-cell co-stimulation, enhancing and sustaining the tumor-killing ability of T cells to overcome the treatment challenges of solid and hematological tumors.Currently, EvolveImmune has developed a rich pipeline, including EVOLVE-104 (ULBP2/CD3/CD2 tri-specific antibody, potential first-in-class), EVOLVE-105 (CD20/CD3/CD2 multi-specific antibody), EVOLVE-106 (CD2/B7-H4/CD3 tri-specific antibody), etc. The company is expected to conduct its first human clinical trial in 2025."We believe that with differentiationCD2 Co-stimulation Strategy"The EVOLVE platform represents a potential next-generation best-in-class T-cell engager platform," said Dr. Stephen Bloch, CEO of EvolveImmune.The bispecific/trispecific (multispecific) antibody track has gained significant momentum in the past few months, with several pharmaceutical giants making moves in this space in 2024. Notably, two recent transactions by companies in China have drawn attention. On October 29, GSK announced a $300 million upfront payment to acquire...Enmu BioAcquisition of CMG1A46 (a trispecific antibody targeting CD19, CD20, and CD3). GSK plans to focus on developing this candidate drug for application in B-cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with the potential to expand into other related autoimmune diseases. Enmu Biotech is also eligible to receive up to $550 million in development and commercialization milestone payments.Moreover, on August 9, Merck &Tongrun BioAnnouncement of a Final Agreement: Merck, through its subsidiary, acquires CN201, a novel CD3xCD19 bispecific antibody from Tongrun Bio in clinical stage. The upfront cash payment for the deal is $700 million, with potential milestone payments up to $600 million. Merck plans to evaluate CN201 as a treatment for B-cell malignancies and explore its potential as a novel therapeutic option for autoimmune diseases.Bispecific/Trispecific/Multispecific Antibodies Have Been One of the Hottest Areas in New Drug Development Over the Past Decade. According to the PharmaCube NextPharma® Database, as of November 1, 2024, there are over 1,300 bispecific/trispecific/multispecific antibody projects under development globally, with Chinese companies becoming the "main force," accounting for half of the projects being developed domestically.Globally Approved Bispecific Antibody Drugs
Data Source: PharmaCube NextPharma®; Data as of 2024-11-01 (Note: Catumaxomab, a CD3/EpCAM bispecific antibody approved by the EU in 2009, has been withdrawn from the market.)In the past three years, bispecific antibodies have seen a "bumper harvest" at the regulatory level. Since 2022, a total of 11 bispecific antibodies have been approved for marketing worldwide, achieving breakthroughs including in indications.(Such as the CD3 bispecific antibody securing the first solid tumor indication, and the first bispecific antibody for ophthalmic diseases being approved for marketing), A Breakthrough in Mechanism of Action(Such as the approval and marketing of two PD-1-based bispecific antibodies)In terms of market performance, Vabysmo, the ophthalmology bispecific antibody approved in January 2022, achieved annual sales of over $2 billion in just two years. Meanwhile, Hemlibra, the bispecific antibody for hemophilia A that was approved earlier, reached a sales peak of $4.485 billion in 2023. In the future, the breakthroughs that bispecific, trispecific, and multispecific antibodies can bring in areas such as oncology and autoimmune diseases are highly anticipated.- Scroll up and down to view references -
[1]https://evolveimmune.com/abbvie-and-evolveimmune-therapeutics-announce-collaboration-and-option-to-license-agreement-to-develop-next-generation-cancer-biotherapeutics/[2]https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-cmg1a46-from-chimagen-biosciences/[3]https://www.businesswire.com/news/home/20240808638055/en/Merck-to-Acquire-Investigational-B-Cell-Depletion-Therapy-CN201-from-Curon-Biopharmaceutical[4]https://www.businesswire.com/news/home/20241001828681/en/Merck-Completes-Acquisition-of-Investigational-B-Cell-Depletion-Therapy-CN201-from-Curon-Biopharmaceutical[5]https://www.globenewswire.com/news-release/2024/08/26/2935368/0/en/Ordspono-odron
Copyright © 2024 PHARMCUBE. All Rights Reserved.Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
